Skip to main content
. 2020 Jun 5;26:e923210-1–e923210-10. doi: 10.12659/MSM.923210

Figure 3.

Figure 3

Exo-eIF4E in NSCLC is strongly relative to disease progression. (A) qPCR showed a comparison of exosome eIF4E levels between NSCLC patients (n = 99) and healthy individuals (n=40). (B) qPCR showed the comparison of exosome eIF4E levels between NSCLC patients with TNM I+II stage (n=39) and III+IV stage (n=60). ** P<0.01, * P<0.05. exo-eIF4E – eoxsomal eIF4E; NSCLC – non-small cell lung cancer; qPCR – quantitative polymerase chain reaction.